bullish
I-Mab (天境生物) IPO: Everest Deal a Valuation Booster
446 Views06 Jan 2020 18:06
I-Mab launched the book building to raise up to USD 111 million via a listing on NASDAQ. In our previous notes, we covered the company’s key...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- I-Mab Placement - Heading in the Right Direction08 Feb 2021
- I-Mab (天境生物) Lock-Up Expiry: A Differentiated Immunotherapy Player Worth Reverse Inquiry08 Jul 2020
- I-Mab (天境生物) IPO Trading: Tiny Float and Undemanding Valuation17 Jan 2020
- I-Mab (天境生物) Pre-IPO: Strong Management and Investor Backing with Differentiated Products04 Nov 2019
x